Oppenheimer Holdings Equities Analysts Reduce Earnings Estimates for Endo International PLC (ENDP)
Endo International PLC (NASDAQ:ENDP) – Research analysts at Oppenheimer Holdings reduced their FY2016 EPS estimates for Endo International PLC in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst M. Ho now expects that the brokerage will post earnings of $3.89 per share for the year, down from their prior estimate of $4.54. Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q4 2016 earnings at $0.93 EPS.
Endo International PLC (NASDAQ:ENDP) last issued its quarterly earnings results on Tuesday, November 8th. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.20. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. The firm had revenue of $894.30 million for the quarter, compared to the consensus estimate of $862.47 million. During the same period in the prior year, the business posted $1.02 earnings per share. The company’s revenue for the quarter was up 18.6% on a year-over-year basis.
ENDP has been the topic of several other reports. Vetr upgraded Endo International PLC from a “buy” rating to a “strong-buy” rating in a report on Friday, October 21st. Mizuho restated a “buy” rating and set a $29.00 target price on shares of Endo International PLC in a report on Monday, September 19th. Northland Securities upgraded Endo International PLC from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, September 29th. Morgan Stanley set a $16.00 target price on Endo International PLC and gave the stock a “hold” rating in a report on Thursday, September 8th. Finally, Piper Jaffray Cos. restated a “neutral” rating and set a $19.00 target price on shares of Endo International PLC in a report on Tuesday, September 27th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Endo International PLC presently has a consensus rating of “Buy” and a consensus target price of $33.52.
Endo International PLC (NASDAQ:ENDP) opened at 17.58 on Friday. The company has a 50-day moving average price of $19.61 and a 200 day moving average price of $19.06. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $63.71. The company’s market cap is $3.92 billion.
Institutional investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC increased its position in Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock valued at $159,000 after buying an additional 4,597 shares in the last quarter. Canada Pension Plan Investment Board increased its position in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares in the last quarter. LS Investment Advisors LLC increased its position in Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock valued at $213,000 after buying an additional 8,247 shares in the last quarter. Icon Advisers Inc. Co. bought a new position in Endo International PLC during the second quarter valued at about $218,000. Finally, IFP Advisors Inc increased its position in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock valued at $226,000 after buying an additional 14,496 shares in the last quarter. Institutional investors own 96.61% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.